Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system

被引：0
作者：
Jing Huang
Yuntao Jia
Shusen Sun
Long Meng
机构：
[1] The First Affiliated Hospital of Chongqing Medical University,Department of Respiratory and Critical Care Medicine
[2] Children’s Hospital of Chongqing Medical University,Department of Pharmacy, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Ch
[3] Western New England University,Department of Pharmacy Practice, College of Pharmacy and Health Sciences
[4] Xiangya Hospital Central South University,Department of Pharmacy
[5] Central South University,Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital
[6] The First Affiliated Hospital of Chongqing Medical University,Department of Pharmacy
来源：
BMC Pharmacology and Toxicology | / 21卷
关键词：
Pharmacovigilance; Data mining; Dipeptidyl Peptidase-4 inhibitors; Adverse event reporting system;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 163 条
[1]  
White J(2009)Efficacy and safety of incretin based therapies: clinical trial data J Am Pharm Assoc 49 S30-S40
[2]  
Ceriello A(2014)DPP-4 inhibitors: pharmacological differences and their clinical implications Expert Opin Drug Saf 13 Suppl 1 S57-491
[3]  
Sportiello L(2017)Evaluation of the expression profile of extrapyramidal symptoms due to antipsychotics by data Mining of Japanese Adverse Drug Event Report (JADER) database Yakugaku Zasshi J Pharm Soc Japan 137 111-411
[4]  
Rafaniello C(2011)Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system PLoS One 6 487-1108
[5]  
Rossi F(2011)Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations Int J Med Sci 8 405-861
[6]  
Kose E(2015)Safety signal detection for platinum compounds in Canadian spontaneous adverse event reports Int J Pharm Pharmaceut Sci 7 1099-497
[7]  
Uno K(2019)Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase® Expert Opin Drug Saf 18 851-8
[8]  
Hayashi H(2018)Pharmacovigilance evaluation of the association between DPP-4 inhibitors and heart failure: stimulated reporting and moderation by drug interactions Diabetes Therapy 9 491-330
[9]  
Sakaeda T(2014)Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance database Acta Diabetol 51 1-2414
[10]  
Kadoyama K(2011)pROC: an open-source package for R and S+ to analyze and compare ROC curves Bmc Bioinformatics 12 e0157753-56
12345678910